Metabolic syndrome (MetS) was associated with an increased incidence of mild cognitive impairment (MCI) and progression to dementia.
Objective
To study the associations between MetS indicators and cerebrospinal fluid (CSF) biomarkers in the participants.
Methods
61 normal cognition, 66 mild MCI, and 135 dementia participants were included in our study, with the results of lumbar puncture and peripheral blood biochemistry. The CSF levels of amyloid-β (Aβ)42 protein, total tau protein, phosphorylated tau protein, and Aβ42/40 ratio, were selected as the biomarkers. The body mass index, the plasma high density lipoprotein cholesterol, uric acid, low density lipoprotein cholesterol, triglyceride, and homocysteine levels were selected as indicators of MetS. Linear regression model was used to analyze the correlation in all participants and different cognitive stages, controlling for age, gender, and APOE genotype.
Results
Our study showed that MetS indicators were associated with CSF biomarkers in participants after adjusting for possible confounding factors, including age, gender, and APOE genotype. The results of our grouping analysis further supported the potential association between plasma MetS indicators and CSF biomarkers in three group. We found that the dementia group showed the greatest correlation coefficient.
Conclusions
The CSF pathological proteins concentrations were associated with MetS indicators, and the correlation coefficient were greater in the dementia stage. These findings suggest that regulating peripheral metabolism may affect the level of pathological proteins in the brain to improve cognitive impairment.
GlennerGGWongCW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun1984; 120: 885–890.
2.
IwatsuboTOdakaASuzukiN, et al.Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals – evidence that an initially deposited species is Aβ42(43). Neuron1994; 13: 45–53.
3.
TamaokaAKondoTOdakaA, et al.Biochemical-evidence for the long-tail form (Aβ1-42/43) of amyloid β protein as a seed molecule in cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun1994; 205: 834–842.
AlbertiKGMMEckelRHGrundySM, et al.Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American Heart Association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation2009; 120: 1640–1645.
6.
NgTPFengLNyuntMSZ, et al.Metabolic syndrome and the risk of mild cognitive impairment and progression to dementia follow-up of the Singapore longitudinal ageing study cohort. JAMA Neurol2016; 73: 456–463.
7.
VanhanenMKoivistoKMoilanenL, et al.Association of metabolic syndrome with Alzheimer disease : a population-based study. Neurology2006; 67: 843–847.
8.
FortiPPisacaneNRiettiE, et al.Metabolic syndrome and risk of dementia in older adults. J Am Geriatr Soc2010; 58: 487–492.
9.
ExaltoLGvan der FlierWMvan BoheemenCJM, et al.The metabolic syndrome in a memory clinic population: relation with clinical profile and prognosis. J Neurol Sci2015; 351: 18–23.
10.
MullerMTangMXSchupfN, et al.Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement Geriatr Cogn Disord2007; 24: 185–192.
11.
FolsteinMFFolsteinSEMcHughPR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
12.
PetersenRCCaraccioloBBrayneC, et al.Mild cognitive impairment: a concept in evolution. J Intern Med2014; 275: 214–228.
13.
Sánchez-GarcíaSGarcía-PeñaCDuque-LópezMX, et al.Anthropometric measures and nutritional status in a healthy elderly population. BMC Public Health2007; 7: 9.
14.
RenZLiYYLiXR, et al.Associations of body mass index, waist circumference and waist-to-height ratio with cognitive impairment among Chinese older adults: based on the CLHLS. J Affect Disord2021; 295: 463–470.
15.
ArvanitakisZCapuanoAWBennettDA, et al.Body mass index and decline in cognitive function in older Black and white persons. J Gerontol Ser A Biol Sci Med Sci2018; 73: 198–203.
16.
MasiSGeorgiopoulosGKhanT, et al.Patterns of adiposity, vascular phenotypes and cognitive function in the 1946 British Birth Cohort. BMC Med2018; 16: 12.
17.
CuiGHGuoHDXuRF, et al.The association of weight status with cognitive impairment in the elderly population of a Shanghai suburb. Asia Pac J Clin Nutr2013; 22: 74–82.
18.
CovaIClericiFMaggioreL, et al.Body mass index predicts progression of mild cognitive impairment to dementia. Dement Geriatr Cogn Disord2016; 41: 172–180.
19.
JooSHYunSHKangDW, et al.Body mass index in mild cognitive impairment according to age, sex, cognitive intervention, and hypertension and risk of progression to Alzheimer's disease. Front Psychiatry2018; 9: 8.
20.
YeBSJangEYKimSY, et al.Unstable body mass index and progression to probable Alzheimer's disease dementia in patients with amnestic mild cognitive impairment. J Alzheimers Dis2016; 49: 483–491.
21.
BellSPLiuDSamuelsLR, et al.Late-life body mass index, rapid weight loss, apolipoprotein E ε4 and the risk of cognitive decline and incident dementia. J Nutr Health Aging2017; 21: 1259–1267.
22.
BesserLMAloscoMLGomezLR, et al.Late-life vascular risk factors and Alzheimer disease neuropathology in individuals with normal cognition. J Neuropathol Exp Neurol2016; 75: 955–962.
23.
AloscoMLDuskinJBesserLM, et al.Modeling the relationships among late-life body mass index, cerebrovascular disease, and Alzheimer's disease neuropathology in an autopsy sample of 1,421 subjects from the national Alzheimer's coordinating center data set. J Alzheimers Dis2017; 57: 953–968.
24.
TianJWangTJJiaK, et al.Nonobese male patients with Alzheimer's disease are vulnerable to decrease in plasma leptin. J Alzheimers Dis2022; 88: 1017–1027.
25.
LiTCLiCILiuCS, et al.Obesity marker trajectories and cognitive impairment in older adults: a 10-year follow-up in Taichung community health study for elders. BMC Psychiatry2022; 22: 11.
26.
BowmanGLShannonJFreiB, et al.Uric acid as a CNS antioxidant. J Alzheimers Dis2010; 19: 1331–1336.
27.
AmesBNCathcartRSchwiersE, et al.Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A1981; 78: 6858–6862.
28.
CervellatiCCremoniniEBosiC, et al.Systemic oxidative stress in older patients with mild cognitive impairment or late onset Alzheimer's disease. Curr Alzheimer Res2013; 10: 365–372.
29.
YuZFBruce-KellerAJGoodmanY, et al.Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res1998; 53: 613–625.
30.
HungSYHuangWPLiouHC, et al.Autophogy protects neuron from Aβ-induced cytotoxicity. Autophagy2009; 5: 502–510.
31.
XiaoQWangJJTianQY, et al.Uric acid mitigates cognitive deficits via TFEB-mediated microglial autophagy in mice models of Alzheimer's disease. Mol Neurobiol2024; 61: 3678–3696.
32.
TranMHYamadaKOlariuA, et al.Amyloid β-peptide induces nitric oxide production in rat hippocampus:: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. FASEB J2001; 15: 1407–1409.
TranMHYamadaKNakajimaA, et al.Tyrosine nitration of a synaptic protein synaptophysin contributes to amyloid β-peptide-induced cholinergic dysfunction. Mol Psychiatr2003; 8: 407–412.
35.
The Lancet. What's next for indigenous health in Australia?Lancet2018; 391: 632–632.
36.
OuYNZhaoBFuY, et al.The association of serum uric acid level, gout, and Alzheimer's disease: a bidirectional Mendelian randomization study. J Alzheimers Dis2022; 89: 1063–1073.
37.
CaoZXuCJYangHX, et al.Associations of BMI and serum urate with developing dementia: a prospective cohort study. J Clin Endocrinol Metab2020; 105: 11.
38.
ScheepersLJacobssonLTHKernS, et al.Urate and risk of Alzheimer's disease and vascular dementia: a population-based study. Alzheimers Dement2019; 15: 754–763.
39.
PanSYChengRJXiaZJ, et al.Risk of dementia in gout and hyperuricaemia: a meta-analysis of cohort studies. BMJ Open2021; 11: 6.
40.
EuserSMHofmanAWestendorpRGJ, et al.Serum uric acid and cognitive function and dementia. Brain2009; 132: 377–382.
41.
HongJYLanTYTangGJ, et al.Gout and the risk of dementia: a nationwide population-based cohort study. Arthritis Res Ther2015; 17: 7.
42.
SinghJAClevelandJD. Gout and dementia in the elderly: a cohort study of Medicare claims. BMC Geriatr2018; 18: 8.
43.
MorellPJurevicsH. Origin of cholesterol in myelin. Neurochem Res1996; 21: 463–470.
44.
DeGrellaRFSimoniRD. Intracellular transport of cholesterol to the plasma membrane. J Biol Chem1982; 257: 14256–14262.
45.
LiDFZhangJLiuQ. Brain cell type-specific cholesterol metabolism and implications for learning and memory. Trends Neurosci2022; 45: 401–414.
46.
O’BrienRJWongPC.Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci2011; 34: 185–204.
47.
van der KantRGoldsteinLSB. Cellular functions of the amyloid precursor protein from development to dementia. Dev Cell2015; 32: 502–515.
48.
WilkinsHMSwerdlowRH. Amyloid precursor protein processing and bioenergetics. Brain Res Bull2017; 133: 71–79.
49.
EhehaltRKellerPHaassC, et al.Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J Cell Biol2003; 160: 113–123.
50.
KaoYCHoPCTuYK, et al.Lipids and Alzheimer's disease. Int J Mol Sci2020; 21: 37.
51.
HeverinMMeaneySLütjohannD, et al.Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res2005; 46: 1047–1052.
52.
ZhangXNXiYDYuHY, et al.27-hydroxycholesterol promotes Aβ accumulation via altering Aβ metabolism in mild cognitive impairment patients and APP/PS1 mice. Brain Pathol2019; 29: 558–573.
53.
ShiZMHongYHZhangK, et al.BAG-1M co-activates BACE1 transcription through NF-κB and accelerates Aβ production and memory deficit in Alzheimer's disease mouse model. Biochim Biophys Acta Mol Basis Dis2017; 1863: 2398–2407.
54.
KimHJJoeYChenY, et al.Carbon monoxide attenuates amyloidogenesis via down-regulation of NF-κB-mediated BACE1 gene expression. Aging Cell2019; 18: 12.
55.
ZhengYDengYGaoJM, et al.Icariside II inhibits lipopolysaccharide-induced inflammation and amyloid production in rat astrocytes by regulating IKK/IκB/NF-κB/BACE1 signaling pathway. Acta Pharmacol Sin2020; 41: 154–162.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
